Clinical Trials
4 trialsNCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
NCT02721433 2020-12-02
REaCT-BTA
Ottawa Hospital Research Institute
Phase 4 Completed
NCT01419717 2019-09-24
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Amgen
Phase 3 Completed
NCT00950911 2014-02-11
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Amgen
Phase 3 Completed